Syncom Formulations (India) Limited (NSE:SYNCOMF)

Market Cap	15.25B
Revenue (ttm)	3.91B
Net Income (ttm)	391.45M
Shares Out	n/a
EPS (ttm)	0.40
PE Ratio	38.95
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,886,836
Average Volume	2,147,789
Open	16.32
Previous Close	16.32
Day's Range	15.90 - 16.62
52-Week Range	10.95 - 27.90
Beta	1.90
RSI	42.99
Earnings Date	May 16, 2025

About NSE:SYNCOMF

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It provides life care, evolve, and right nutrition products under the Cratus brand. In addition, the company engages in the trading of comm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 998
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SYNCOMF

Financial Performance

In 2023, NSE:SYNCOMF's revenue was 2.63 billion, an increase of 17.45% compared to the previous year's 2.24 billion. Earnings were 253.14 million, an increase of 26.13%.